The risk for respiratory syncytial virus-related hospitalizations is elevated in children with chronic medical conditions ...

A large-scale real-world study in the USA has reinforced the effectiveness of Beyfortus (nirsevimab-alip), the respiratory ...

HHS Secretary Robert F. Kennedy Jr. formally accepted recommendations that would require all vaccine manufacturers to ...

Cancer drug Keytruda maker Merck buys Verona before patent cliff Merck’s blockbuster drug Keytruda to lose key patent protections in 2028 ...

Merck & Co., Inc. (NYSE:MRK) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. The company has a strong ...

AS01-adjuvanted RSV and shingles vaccines were tied to a lower dementia risk in older adults. Compared with flu vaccine recipients, those who had the AS01 RSV shot had 29% more dementia-free time ...

Hospital readmission risk in pediatric patients was higher in those who were first admitted for RSV than in those who were first admitted for influenza or hMPV.

A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...

MRK's regulatory filing for once-daily HIV pill DOR/ISL gets FDA acceptance, with a decision expected by April 2026.

The CDC has updated lowered the recommended age for RSV vaccination from 60 years to 50 years for adults with some conditions with RFK Jr's approval. HealthDay News — Adults as young as 50 may now ...

Adults as young as 50 may now qualify for an respiratory synctial virus vaccine if they have certain health conditions.

Verona Pharma surged by 20.62 percent on Wednesday to end at $104.77 per share following news that it was being acquired by US-based pharmaceutical company Merck for $10 billion.